Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q3 FY2022 Earnings Presentation
12 slides from Gland Pharma's earnings presentation, Jan 21, 2022
Slide 1: Gland Pharma Limited Financial Results Q3 FY22
Gland Pharma Limited Financial Results Q3’FY22 21st January 2022
Slide 2: Safe Harbor Statement
Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation
Slide 3: Financial Highlights (1/3)
Financial Highlights (1/3) Strong growth across geographies drives profitability; R&D investments in line with business strategy Revenue from Operations EBITDA (1) / EBITDA Margin (2) (INR Mn) (INR Mn / %) 13,205 32,977 10,621 10,633 3,946 8,594 25,751 2,994 38% 36% 40% 33% Q3 FY21 Q3 FY22 9M FY21 9
Slide 4: Financial Highlights (2/3)
Financial Highlights (2/3) Balance sheet continues to remain strong while CapEx remains in line with growth plans Net Worth (1) Cash and Bank Balances / Net Cash (2) (INR Mn) (INR Mn) 68,708 59,032 12,250 32,846 32,807 12,250 30,058 30,017 56,458 46,782 Mar'21 Dec'21 Mar'21 Dec'21 Networth Fresh iss
Slide 5: Financial Highlights (3/3)
Financial Highlights (3/3) Focus on Capital efficiency and healthy return ratios Asset Turnover Ratio (1)(2) ROCE (ex-cash)(3) / ROCE (4) / RONW (5) (%) 3.2 2.9 2.8 35% 35% 34% 21% 21% 19% 21% 21% 19% 0.7 0.7 0.7 (8) (8) Total asset turnover Fixed asset turnover 9M FY21 FY21 9M FY22 9M FY21 FY21 9M
Slide 6: P&L Highlights
P&L Highlights (INR Mn) YoY YoY Particulars Q3 FY22 Q3 FY21 9M FY22 9M FY21 Q2 FY22 growth growth Revenue From operations 10,633 8,594 24% 32,977 25,751 28% 10,805 Other Income 457 351 30% 1,587 876 81% 512 Total income 11,090 8,945 24% 34,564 26,627 30% 11,317 Gross Margin(1) 5,599 4,526 24% 17,338
Slide 7: USA, Europe, Canada and Australia (Core Markets)
USA, Europe, Canada and Australia (Core Markets) Revenue: 9M FY22: Rs. 20,342 Mn Q3 FY22: Rs. 6,652 Mn YoY Growth: 17% (20%) YoY Growth: 10% (18%) Key products driving the growth in Q3 FY22 include (%) - including India sales for our core markets Micafungin Sodium, Ketorolac Tromethamine and Hepar
Slide 8: Rest of the World Markets
Rest of the World Markets Our strategy of expanding our product portfolio in 9M FY22: Rs. 6,579 Mn Q3 FY22: Rs. 2,031 Mn YoY Growth: 64% YoY Growth: 88% identified geographies has shown good results for rest of the world markets. Rest of the World Markets Key markets contributing to the growth c
Slide 9: India (Domestic Market)
India (Domestic Market) India sales grew by 31% on account of volume growth 9M FY22: Rs. 6,056 Mn Q3 FY22: Rs. 1,950 Mn YoY Growth: 40% YoY Growth: 31% of existing products along with ramp-up of launched products for the export markets. India (Domestic Market) The India sales stood at 18% of our
Slide 10: Focus on expanding capabilities in Complex Injectables
Focus on expanding capabilities in Complex Injectables Our near-term focus remains on establishing a strong portfolio of complex injectables Working on development of 17 Complex Injectables in first Expanding capabilities in: phase: Peptides Completed four complex injectable filings in Q3 FY22 w
Slide 11: Building capability for Biotech and Vaccine Manufacturing
Building capability for Biotech and Vaccine Manufacturing We are making investments towards creating robust infrastructure for the vaccine and bio-similar space We are exploring partnerships to accelerate entry into the Biologics CDMO market which is estimated at nearly USD 13 Bn, growing at a C
Slide 12: GLAND
Registered Office Corporate Office: Gland Pharma Limited Gland Pharma Limited Survey No. 143-148, 150 & 151 Plot No. 11 & 84, TSIIC Phase: IV Near Gandimaisamma 'X' Roads Pashamylaram (V), Patancheru (M), D.P. Pally, Dundigal Gandimaisamma Mandal Sangareddy District Medchal-Malkajgiri District Hyder